©2021-2032 All Rights Reserved. Online Journal of Bioinformatics. You may not store these pages in any form except for your own personal use. All other usage or distribution is illegal under international copyright treaties. Permission to use any of these pages in any other way besides the before mentioned must be gained in writing from the publisher. This article is exclusively copyrighted in its entirety to firstname.lastname@example.org publications. This article may be copied once but may not be, reproduced or re-transmitted without the express permission of the editors. Linking: To link to this page or any pages linking to this page you must link directly to this page only here rather than put up your own page.
Online Journal of Bioinformatics©
Volume 23 (3):287-297, 2022.
In silico binding dipeptidyl peptidase target protein for diabetes mellitus 2.
Rajeev Sharmah, Subrata Sinha, Surabhi Johari
Center for Bioinformatics Studies, Department of Life sciences, Dibrugarh University, Dibrugarh Assam, India.
Sharmah R, Sinha S, Johari S., In silico binding dipeptidyl peptidase target protein for diabetes mellitus 2, Onl J Bioinform., 23 (3):287-297, 2022. Diabetes mellitus type 2 is caused by lack of insulin production. Di-peptidyl peptidase IV (DPP IV) protease degrades incretins that stimulate secretion of insulin so its inhibition should boost insulin. We retrieved sequence DPP IV for In silico docking. We designed drug using methylamine as lead molecule. Results from OSIRIS and MOLINSPIRATION show the methyl amines with drug score of 0.83. The drug (3-[3-(methyl amino) cyclopentyl] pentane-1, 2-diol) was non-mutagenic, irritant, tumerogenic or reproductive effects with low molecular weight drug.
Key-words: Diabetes, Glucagon like peptide, Dipeptidyl Peptidase IV, Drug.
FULL-TEXT (SUBSCRIBE OR PURCHASE TITLE)